Quick Takeaways
- BB BIOTECH AG filed SCHEDULE 13G/A for Black Diamond Therapeutics, Inc. Common Stock (BDTX).
- Disclosed ownership: 15%.
- Date of event: 31 Dec 2024.
BB BIOTECH AG - 31 Dec 2024 SCHEDULE 13G/A Report for Black Diamond Therapeutics, Inc. Common Stock (BDTX)
- Filing Manager
- BB BIOTECH AG
- Reporting Manager
- BB Biotech AG
- Symbol
- BDTX
- Shares outstanding
- 56,409,530 shares
- Disclosed Ownership
- 8,517,839 shares
- Ownership
- 15%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 14:36:15 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 21 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BB BIOTECH AG disclosed 15% ownership in Black Diamond Therapeutics, Inc. Common Stock (BDTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 14:36.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 15% | 8,517,839 | 0 | 8,517,839 | /s/ Martin Gubler | Martin Gubler/Signatory Authority | |
| Biotech Growth N.V. | 15% | 8,517,839 | 0 | 8,517,839 | /s/ Jan Bootsma | Jan Bootsma/Signatory Authority |